1.Special issue on neurodegenerative diseases and their therapeutic approaches.
Experimental & Molecular Medicine 2015;47(3):e146-
No abstract available.
Humans
;
Neurodegenerative Diseases/*drug therapy/*etiology
2.Effects of resveratrol-induced cellular autophagy in control of neurodegenerative diseases.
Acta Pharmaceutica Sinica 2016;51(1):18-22
Cellular autophagy is a major degradative pathway for clearance of aggregate-prone proteins and damaged organelles. It plays an important role in regulating cellular homeostasis, cell growth and development, and disease development. Dysfunctional autophagy contributes to the pathology of various neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease, in which specific pathological protein accumulation occurs. A growing body of evidence suggests that resveratrol plays a significantly role in the regulation of autophagy and clearance of pathological proteins. Resveratrol is a potential drug for neurodegenerative diseases therapy. This review focuses on the effects of resveratrol on cellular autophagy and clinical application in the control of neurodegenerative diseases.
Alzheimer Disease
;
Autophagy
;
Humans
;
Huntington Disease
;
Neurodegenerative Diseases
;
drug therapy
;
Parkinson Disease
;
Stilbenes
;
pharmacology
3.Cellular models for disease exploring and drug screening.
Protein & Cell 2010;1(4):355-362
The biopharmaceutical industry has been greatly promoted by the application of drug and disease models, including both animal and cellular models. In particular, the emergence of induced pluripotent stem cells (iPSC) makes it possible to create a large number of disease-specific cells in vitro. This review introduces the most widely applied models and their specialties.
Animals
;
Drug Evaluation, Preclinical
;
methods
;
Humans
;
Induced Pluripotent Stem Cells
;
cytology
;
Models, Biological
;
Neurodegenerative Diseases
;
therapy
4.Research progress on traditional Chinese medicine in treatment of neurodegenerative diseases by delaying neurovascular unit aging.
Chun-Miao YING ; Fei-Xiang LIU ; Xiao-Long PAN ; Fei-Yan FAN ; Na CHEN ; Yun-Ke ZHANG
China Journal of Chinese Materia Medica 2023;48(15):4060-4071
Neurodegenerative diseases are a collective term for a large group of diseases caused by degenerative changes in nerve cells. Aging is the main risk factor for neurodegenerative diseases. The neurovascular unit(NVU) is the smallest functional unit of the brain, which regulates brain blood flow and maintains brain homeostasis. Accelerated aging of NVU cells directly impairs NVU function and leads to the occurrence of various neurodegenerative diseases. The intrinsic mechanisms of NVU cell aging are complex and involve oxidative stress damage, loss of protein homeostasis, DNA damage, mitochondrial dysfunction, immune inflammatory response, and impaired cellular autophagy. In recent years, studies have found that traditional Chinese medicine(TCM) can inhibit NVU aging through multiple pathways and targets, exerting a brain-protective effect. Therefore, this article aimed to provide a theoretical basis for further research on TCM inhibition of NVU cell aging and references for new drug development and clinical applications by reviewing its mechanisms of anti-aging, such as regulating relevant proteins, improving mitochondrial dysfunction, reducing DNA damage, lowering inflammatory response, antioxidant stress, and modulating cellular autophagy.
Humans
;
Medicine, Chinese Traditional
;
Neurodegenerative Diseases/drug therapy*
;
Brain
;
Aging
;
Neurons
;
Blood-Brain Barrier
5.Pharmacological Treatment in Parkinson's Disease
Journal of the Korean Neurological Association 2019;37(4):335-344
Parkinson's disease is one of the most common neurodegenerative disorders world widely. Although curable therapies are practically not available yet, symptomatic managements using anti-Parkinson medications have shown to be quite effective to improve patients' quality of life. The discovery of dopaminergic deficits in Parkinson's disease in 1960s have brought about the human clinical trials of levodopa, which opened an “Era of Dopamine” in treatment history of the Parkinson's disease. Levodopa still remains gold standard. Dopamine agonists have proved their efficacies and delayed the development of long-term complications of levodopa use. Inhibitors of respective enzyme monoamine oxidase-B and catechol-O-methyltransferase, anticholinergics, and amantadine strengthen the therapeutic effects via either monotherapy or adjunctive way. Strategy of continuous dopaminergic stimulation and disease modification are weighing in current advances. This article is providing evidence-based review of pharmacological treatment of Parkinson's disease from early to advanced stages as well as management its unavoidable adverse reactions.
Amantadine
;
Catechol O-Methyltransferase
;
Cholinergic Antagonists
;
Dopamine Agonists
;
Drug Therapy
;
Humans
;
Levodopa
;
Neurodegenerative Diseases
;
Parkinson Disease
;
Quality of Life
;
Therapeutic Uses
6.Natural antioxidants in the management of Parkinson's disease: Review of evidence from cell line and animal models.
Reem ABDUL-LATIF ; Ieva STUPANS ; Ayman ALLAHHAM ; Benu ADHIKARI ; Thilini THRIMAWITHANA
Journal of Integrative Medicine 2021;19(4):300-310
Parkinson's disease (PD) is a chronic progressive neurodegenerative disease. It results from the death of dopaminergic neurons. The pathophysiological mechanisms in idiopathic PD include the production of α-synuclein and mitochondrial respiratory function-affecting complex I, caused by reactive oxygen species. Therefore, the use of natural antioxidants in PD may provide an alternative therapy that prevents oxidative stress and reduces disease progression. In this review, the effects of hydroxytyrosol, Ginkgo biloba, Withania somnifera, curcumin, green tea, and Hypericum perforatum in PD animal and cell line models are compared and discussed. The reviewed antioxidants show evidence of protecting neural cells from oxidative stress in animal and cell models of PD. However, the clinical efficacy of these phytochemicals needs to be optimised and further investigated.
Animals
;
Antioxidants/pharmacology*
;
Cell Line
;
Disease Models, Animal
;
Models, Animal
;
Neurodegenerative Diseases
;
Oxidative Stress
;
Parkinson Disease/drug therapy*
7.Roles of Gut Microbiota in Pathogenesis of Alzheimer's Disease and Therapeutic Effects of Chinese Medicine.
Ying-Xin SUN ; Xi-Juan JIANG ; Bin LU ; Qing GAO ; Ye-Fei CHEN ; Dan-Bin WU ; Wen-Yun ZENG ; Lin YANG ; Hu-Hu LI ; Bin YU
Chinese journal of integrative medicine 2022;28(11):1048-1056
Alzheimer's disease (AD) is the most common neurodegenerative disease characterized by progressive cognitive impairment. The pathogenesis of AD is complex, and its susceptibility and development process are affected by age, genetic and epigenetic factors. Recent studies confirmed that gut microbiota (GM) might contribute to AD through a variety of pathways including hypothalamic pituitary adrenal axis and inflflammatory and immune processes. CM formula, herbs, and monomer enjoy unique advantages to treat and prevent AD. Hence, the purpose of this review is to outline the roles of GM and its core metabolites in the pathogenesis of AD. Research progress of CMs regarding the mechanisms of how they regulate GM to improve cognitive impairment of AD is also reviewed. The authors tried to explore new therapeutic strategies to AD based on the regulation of GM using CM.
Humans
;
Alzheimer Disease/drug therapy*
;
Gastrointestinal Microbiome
;
Hypothalamo-Hypophyseal System
;
Medicine, Chinese Traditional
;
Neurodegenerative Diseases
;
Pituitary-Adrenal System
;
Brain/pathology*
8.Neuroprotective effects of curcumin.
China Journal of Chinese Materia Medica 2009;34(24):3173-3175
Traditionally, turmeric has been put to use as a food additive and herbal medicine in Asia. Curcumin is an active principle of the perennial herb curcuma longa (commonly known as turmeric). Recent evidence suggests that curcumin has activities with potential for neuroprotective efficacy, including anti-inflammatory, antioxidant, and antiprotein-aggregate activities. In the current review, we provide the newly evidence for the potential role of curcumin in the neuroprotective effects of neurodegenerative diseases like Alzheimer's disease (AD).
Alzheimer Disease
;
drug therapy
;
pathology
;
Animals
;
Curcuma
;
chemistry
;
Curcumin
;
chemistry
;
therapeutic use
;
Humans
;
Neurodegenerative Diseases
;
drug therapy
;
pathology
;
Neuroprotective Agents
;
chemistry
;
therapeutic use
;
Plant Extracts
;
chemistry
;
therapeutic use
9.The role of mitochondrial DNA mutation on neurodegenerative diseases.
Moon Yong CHA ; Dong Kyu KIM ; Inhee MOOK-JUNG
Experimental & Molecular Medicine 2015;47(3):e150-
Many researchers have reported that oxidative damage to mitochondrial DNA (mtDNA) is increased in several age-related disorders. Damage to mitochondrial constituents and mtDNA can generate additional mitochondrial dysfunction that may result in greater reactive oxygen species production, triggering a circular chain of events. However, the mechanisms underlying this vicious cycle have yet to be fully investigated. In this review, we summarize the relationship of oxidative stress-induced mitochondrial dysfunction with mtDNA mutation in neurodegenerative disorders.
Animals
;
DNA, Mitochondrial/*genetics
;
Humans
;
Mitochondria/drug effects/genetics/metabolism
;
Molecular Targeted Therapy
;
*Mutation
;
Neurodegenerative Diseases/drug therapy/*genetics/metabolism
;
Reactive Oxygen Species/metabolism
10.APE1/Ref-1 as an emerging therapeutic target for various human diseases: phytochemical modulation of its functions.
Shweta THAKUR ; Bibekananda SARKAR ; Ravi P CHOLIA ; Nandini GAUTAM ; Monisha DHIMAN ; Anil K MANTHA
Experimental & Molecular Medicine 2014;46(7):e106-
Apurinic/apyrimidinic endonuclease 1 (APE1) is a multifunctional enzyme involved in the base excision repair (BER) pathway, which repairs oxidative base damage caused by endogenous and exogenous agents. APE1 acts as a reductive activator of many transcription factors (TFs) and has also been named redox effector factor 1, Ref-1. For example, APE1 activates activator protein-1, nuclear factor kappa B, hypoxia-inducible factor 1alpha, paired box gene 8, signal transducer activator of transcription 3 and p53, which are involved in apoptosis, inflammation, angiogenesis and survival pathways. APE1/Ref-1 maintains cellular homeostasis (redox) via the activation of TFs that regulate various physiological processes and that crosstalk with redox balancing agents (for example, thioredoxin, catalase and superoxide dismutase) by controlling levels of reactive oxygen and nitrogen species. The efficiency of APE1/Ref-1's function(s) depends on pairwise interaction with participant protein(s), the functions regulated by APE1/Ref-1 include the BER pathway, TFs, energy metabolism, cytoskeletal elements and stress-dependent responses. Thus, APE1/Ref-1 acts as a 'hub-protein' that controls pathways that are important for cell survival. In this review, we will discuss APE1/Ref-1's versatile nature in various human etiologies, including neurodegeneration, cancer, cardiovascular and other diseases that have been linked with alterations in the expression, subcellular localization and activities of APE/Ref-1. APE1/Ref-1 can be targeted for therapeutic intervention using natural plant products that modulate the expression and functions of APE1/Ref-1. In addition, studies focusing on translational applications based on APE1/Ref-1-mediated therapeutic interventions are discussed.
Animals
;
DNA Damage
;
DNA Repair
;
DNA-(Apurinic or Apyrimidinic Site) Lyase/analysis/genetics/*metabolism
;
Humans
;
*Molecular Targeted Therapy/methods
;
Neoplasms/*drug therapy/genetics/*metabolism
;
Neurodegenerative Diseases/*drug therapy/genetics/*metabolism
;
Oxidative Stress
;
Phytochemicals/pharmacology/*therapeutic use
;
Polymorphism, Genetic
;
Protein Interaction Maps